Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Tomas Radivoyevitch, Robert M. Dean, Bronwen E. Shaw, Ruta Brazauskas, Heather R. Tecca, Remco J. Molenaar, Minoo Battiwalla, Bipin N. Savani, Mary E.D. Flowers, Kenneth R. Cooke, Betty K. Hamilton, Matt Kalaycio, Jaroslaw P. Maciejewski, Ibrahim Ahmed, Görgün Akpek, Ashish Bajel, David Buchbinder, Jean Yves Cahn, Anita D'Souza, Andrew DalyZachariah DeFilipp, Siddhartha Ganguly, Mehdi Hamadani, Robert J. Hayashi, Peiman Hematti, Yoshihiro Inamoto, Nandita Khera, Tamila Kindwall-Keller, Heather Landau, Hillard Lazarus, Navneet S. Majhail, David I. Marks, Richard F. Olsson, Sachiko Seo, Amir Steinberg, Basem M. William, Baldeep Wirk, Jean A. Yared, Mahmoud Aljurf, Muneer H. Abidi, Heather Allewelt, Amer Beitinjaneh, Rachel Cook, Robert F. Cornell, Joseph W. Fay, Gregory Hale, Jennifer Holter Chakrabarty, Sonata Jodele, Kimberly A. Kasow, Anuj Mahindra, Adriana K. Malone, Uday Popat, J. Douglas Rizzo, Harry C. Schouten, Anne B. Warwick, William A. Wood, Mikkael A. Sekeres, Mark R. Litzow, Robert P. Gale, Shahrukh K. Hashmi

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995–2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005–2010 versus 1995–1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5–10 times the background rate. In contrast, relative risks were 10–50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.

Original languageEnglish (US)
Pages (from-to)130-136
Number of pages7
JournalLeukemia Research
Volume74
DOIs
StatePublished - Nov 2018

Keywords

  • AML
  • Autotransplant
  • CIBMTR
  • MDS
  • New cancers
  • SEER
  • Therapy-related

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma'. Together they form a unique fingerprint.

Cite this